IGC Pharma/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IGC Pharma
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Ticker
$IGC
Sector
Primary listing
AMEX
Employees
70
Headquarters
Website
IGC Pharma Metrics
BasicAdvanced
$27m
-
-$0.08
0.45
-
Price and volume
Market cap
$27m
Beta
0.45
52-week high
$0.50
52-week low
$0.24
Average daily volume
678k
Financial strength
Current ratio
1.324
Quick ratio
0.787
Long term debt to equity
1.693
Total debt to equity
1.804
Profitability
EBITDA (TTM)
-7.524
Gross margin (TTM)
46.20%
Net profit margin (TTM)
-582.82%
Operating margin (TTM)
-731.92%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-50.31%
Return on equity (TTM)
-83.34%
Valuation
Price to revenue (TTM)
20.613
Price to book
3.13
Price to tangible book (TTM)
7.89
Price to free cash flow (TTM)
-3.641
Free cash flow yield (TTM)
-27.47%
Free cash flow per share (TTM)
-0.076
Growth
Revenue change (TTM)
-6.51%
Earnings per share change (TTM)
-57.08%
3-year revenue growth (CAGR)
17.72%
10-year revenue growth (CAGR)
-18.65%
3-year earnings per share growth (CAGR)
-34.20%
10-year earnings per share growth (CAGR)
-9.84%
IGC Pharma News
AllArticlesVideos
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Accesswire·1 week ago
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
Accesswire·1 week ago
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs